Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $67.00

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received a consensus rating of “Moderate Buy” from the thirteen research firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $67.00.

NTLA has been the subject of several research analyst reports. The Goldman Sachs Group lowered Intellia Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $136.00 to $32.00 in a research note on Friday, February 23rd. Canaccord Genuity Group raised their price target on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. Finally, Wolfe Research began coverage on shares of Intellia Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $23.60 on Tuesday. Intellia Therapeutics has a 1 year low of $19.37 and a 1 year high of $47.48. The firm has a 50 day moving average price of $26.06 and a 200 day moving average price of $27.30. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -4.36 and a beta of 1.85.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. The company had revenue of ($1.92) million during the quarter, compared to analysts’ expectations of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same period in the previous year, the company earned ($1.40) EPS. Sell-side analysts predict that Intellia Therapeutics will post -5.57 EPS for the current year.

Insider Activity at Intellia Therapeutics

In other news, EVP James Basta sold 2,297 shares of Intellia Therapeutics stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at $2,691,027.29. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.00% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC increased its holdings in Intellia Therapeutics by 14.7% in the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock valued at $347,966,000 after buying an additional 1,463,820 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Intellia Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock valued at $254,514,000 after acquiring an additional 155,579 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Intellia Therapeutics by 3.7% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,520,295 shares of the company’s stock worth $111,312,000 after purchasing an additional 125,639 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Intellia Therapeutics by 1.4% in the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after purchasing an additional 36,630 shares during the period. Finally, Federated Hermes Inc. increased its stake in Intellia Therapeutics by 13.8% during the fourth quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company’s stock valued at $61,477,000 after purchasing an additional 244,722 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.